Sign in Subscribe

Alex Chompff

Combination Therapy Shows Activity in KRAS G12C-Mutated Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Combination Therapy Shows Activity in KRAS G12C-Mutated Metastatic CRC A phase 1b/2 trial found that ifebemtinib plus garsorasib demonstrated anticancer activity and manageable safety in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer, though the improvement in response rate did not

Whole-Genome Electrical Impedance Assay Detects DNA Hypomethylation for CRC Screening

Skip to content The CRC Digest ▪ SCREENING Whole-Genome Electrical Impedance Assay Detects DNA Hypomethylation for CRC Screening A rapid, label-free cell-free DNA assay measures global DNA hypomethylation—a hallmark of colorectal cancer—using electrical impedance to differentiate healthy individuals from those with cancer in a retrospective validation study. (Computational and

Total Neoadjuvant Therapy With Long-Course Radiotherapy Studied in High-Risk Rectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Total Neoadjuvant Therapy With Long-Course Radiotherapy Studied in High-Risk Rectal Cancer The multicenter phase III TNTCRT trial compared total neoadjuvant therapy using long-course radiotherapy versus chemoradiotherapy in patients with high-risk locally advanced rectal cancer. (Journal of Clinical Oncology) This content is informational

Final Analysis of DEEPER Trial in RAS/BRAF Wild-Type Metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Final Analysis of DEEPER Trial in RAS/BRAF Wild-Type Metastatic CRC The DEEPER trial presents final analysis of long-term survival outcomes comparing modified-FOLFOXIRI plus cetuximab versus bevacizumab in patients with RAS and BRAF wild-type metastatic colorectal cancer. (Journal of Clinical Oncology) This

COMMIT Trial Compares Immunotherapy Alone to Chemo-Plus-Immunotherapy in dMMR Metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA COMMIT Trial Compares Immunotherapy Alone to Chemo-Plus-Immunotherapy in dMMR Metastatic CRC The COMMIT trial is a randomized study comparing atezolizumab alone versus mFOLFOX6/bevacizumab/atezolizumab as first-line treatment of deficient DNA mismatch repair metastatic colorectal cancer. (Journal of Clinical Oncology) This content

Digital Platform Validated for Colorectal Cancer Risk Stratification and Personalized Screening Recommendations

Skip to content The CRC Digest Digital Platform Validated for Colorectal Cancer Risk Stratification and Personalized Screening Recommendations Validation study of ChequeáTuColon, a digital tool designed to stratify colorectal cancer risk, detect alarm symptoms, and provide personalized guideline-based screening recommendations, shows accuracy when compared to expert gastroenterologist assessments. (Digestive Diseases

Blood-Based Immune Profiling Identifies Circulating Th1-Like Cells as Biomarker for Advanced Adenomas

Skip to content The CRC Digest Blood-Based Immune Profiling Identifies Circulating Th1-Like Cells as Biomarker for Advanced Adenomas Prospective study of 104 FOBT-positive patients used spectral cytometry and machine learning to identify circulating Th1-like cells as a potential blood biomarker to improve detection of advanced colorectal adenomas and optimize colonoscopy

Structured Surveillance in Lynch Syndrome Shows Effectiveness and Identifies Unmet Needs

Skip to content The CRC Digest Structured Surveillance in Lynch Syndrome Shows Effectiveness and Identifies Unmet Needs Retrospective analysis of 517 Lynch syndrome carriers undergoing structured multiorgan surveillance over 4,827 person-years reports cancer incidence rates, tumor distribution, and modes of detection to assess adherence and effectiveness of guideline-based follow-up.

Immunotherapy Combination Achieves Complete Response and Polyp Regression in dMMR Colorectal Cancer

Skip to content The CRC Digest Immunotherapy Combination Achieves Complete Response and Polyp Regression in dMMR Colorectal Cancer Case report from the NOUS-209-01 trial describes a patient with mismatch repair-deficient colorectal cancer who achieved complete pathologic response and significant colonic polyp regression following treatment with Nous-209 plus pembrolizumab. (Journal of

Scoping Review Identifies Barriers to Diagnostic Colonoscopy After Positive Stool-Based Screening

Skip to content The CRC Digest ▪ SCREENING Scoping Review Identifies Barriers to Diagnostic Colonoscopy After Positive Stool-Based Screening Systematic review synthesizes barriers and facilitators to completing diagnostic colonoscopy after a positive non-invasive stool-based screening test (FIT, gFOBT, or multitarget stool DNA), emphasizing that timely follow-up colonoscopy is essential for reducing